UltraThineer, the world's first minimal to no-prep, 3D printed zirconia veneer, has been featured in a new clinical case demonstrating its ability to transform a patient's smile affected by severe ...

The objective response rate was 65.7% in the encorafenib/cetuximab with mFOLFOX6 arm, compared with 45.6% in the encorafenib/cetuximab alone group and 37.4% in the control arm. Patients in the triplet ...

A law written by Ohio State Sen. Jerry Cirino already is having a chilling effect, as Kent State University is forced to shut down centers that provided solace and resources for women and LGBTQ ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

OrigAMI-3, involving 700 patients across more than 20 countries, compares amivantamab (Rybrevant) plus FOLFIRI to standard regimens of either cetuximab or bevacizumab plus FOLFIRI, which consists of ...

Braftovi (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an ...

Scottie Scheffler continued his dominance on the PGA Tour, winning the Memorial. However, his one-year-old son, Bennett, was all of the afterward.

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

Key takeaways. Enhertu plus pertuzumab showed a 44% reduction in disease progression or death versus the current standard-of-care THP regimen.. The combination therapy achieved a median PFS of 40.7 ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...